Skip to search formSkip to main contentSkip to account menu

KW-3902

Known as: KW 3902 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

rolofylline

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Use of KW-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload
Methods of treating patients with acute fluid overload comprising administering diuretic therapy and an amount of KW-3902, a… 
2006
2006
Abstract 2164: Effect of the Adenosine A1 Receptor Antagonist, KW-3902, on Diuresis and Renal Function in Patients with Acute Decompensated Heart Failure Refractory to Maximum Doses of Conventional…
Background: Some patients with acute decompensated heart failure (ADHF) reach a point where high doses of diuretics are… 
2006
2006
Abstract 2731: The Effect of KW-3902, an Adenosine A1 Receptor Antagonist, on Renal Function and Renal Plasma Flow in Subjects With Heart Failure and Renal Impairment: A Randomized, Double-Blind…
2004
2004
Method of urinary normalisation in renal malfunction
FIELD: medicine. SUBSTANCE: invention refers to pharmaceutical compound to improve renal function that contains KW-3902 30 mg or… 
2003
2003
The Anti-apoptotic Effects of KW-3902, A Selective Adenosine A1 Receptor Antagonist, in Hemorrhagic Shock Rat Heart
1999
1999
Protective Effects of KW-3902, an Adenosine A1-Receptor Antagonist, Against the Nephropathy Induced by Repeated Administration of Cisplatin in Rats
We investigated the possible renal protective effect of KW-3902 (8-(noradamantan-3-yl)-1 ,3-dipropyl-xanthine), a novel adenosine… 
1994
1994
Effects of KW-3902, a novel adenosine A1-receptor antagonist, on cephaloridine-induced acute renal failure in rats.
We investigated the possible renal protective effects of KW-3902 (8-(noradamantan-3-yl)-1,3-dipropylxanthine), a selective and…